For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Hexarelin (examorelin) is a synthetic hexapeptide GH secretagogue developed by Mediolanum Farmaceutici. It is the most potent traditional GHRP for acute GH release -- exceeding maximal GHRH -- and uniquely binds both GHS-R1a and cardiac CD36 receptors. Three human cardiac studies demonstrate acute GH-independent improvements in left ventricular ejection fraction in healthy volunteers (n=7), GH-deficient patients, coronary artery disease patients (n=24), and severe cardiomyopathy patients (n=13). The defining practical limitation is pronounced tachyphylaxis: GH response attenuates 50 to 75% within weeks of daily use. Phase 2 development reached for GH deficiency and congestive heart failure but was discontinued in 2005 for commercial rather than safety reasons.
Hexarelin has a genuinely distinctive pharmacological profile within the GH secretagogue class: it is the only traditional GHRP with documented GH-independent cardioprotective effects in human patients, mediated through a specific cardiac receptor (CD36) that other GHRPs do not engage. The human cardiac data -- three separate studies showing acute LVEF improvement in healthy subjects, GH-deficient patients, coronary artery disease patients, and severe cardiomyopathy patients -- is the strongest cardioprotective human signal of any peptide GH secretagogue in this database.
The defining limitation is tachyphylaxis. Repeated daily hexarelin administration causes progressive attenuation of GH release -- a 50 to 75% decrease in peak GH response over weeks to months of continuous use. This is more pronounced than with ipamorelin or GHRP-2 and is the primary reason the research community typically recommends strict cycling protocols (8 to 16 weeks on, 4 to 6 weeks off) and why chronic GH elevation for body composition purposes is less reliably achieved than with other secretagogues.
Phase 2 development for both GH deficiency and congestive heart failure was discontinued in 2005 by Mediolanum Farmaceutici for stated commercial and strategic reasons, not for safety failure or negative efficacy data. This distinction matters: hexarelin was not abandoned because it did not work. The cardiac indication in particular had positive acute human data. The absence of approved status reflects commercial decisions, not a resolved negative efficacy question.
WADA explicitly names examorelin (hexarelin) under S2.2 GH-Releasing Peptides, prohibited at all times. Athletes subject to doping control face a positive test from any use.
Hexarelin was synthesized in the early 1990s by Romano Deghenghi and colleagues at Europeptides, and developed clinically by Mediolanum Farmaceutici in Italy. The structural innovation was replacing D-tryptophan at position 2 of GHRP-6 with 2-methyltryptophan (D-2-MeTrp), which increased GHS-R1a binding affinity and potency while also adding a second receptor interaction not shared by GHRP-6: binding to CD36 in cardiac tissue.
Systematic Phase 1 dose-response work by the Turin endocrinology group (Ghigo, Arvat, and colleagues) established hexarelin's human GH-releasing pharmacology in the 1990s, confirming dose-dependent GH release peaking at 30 minutes after IV administration, with the 2 mcg/kg IV dose producing GH responses exceeding those of maximal GHRH. This body of work positioned hexarelin as the most potent of the traditional GHRPs.
The cardiac pharmacology emerged as a distinct and unexpected research direction. When clinical investigators observed that hexarelin's cardiac effects in GH-deficient and hypophysectomized subjects were not abolished by the absence of GH secretion, it became clear that a GH-independent mechanism was operating. Subsequent work identified the specific cardiac receptor as CD36, a multifunctional scavenger receptor expressed in cardiomyocytes and microvascular endothelial cells that does not bind ghrelin or GHRP-2 at comparable affinity. This CD36 pathway is now recognized as the principal mediator of hexarelin's cardioprotective effects.
Phase 2 trials for GH deficiency and congestive heart failure were underway but discontinued in 2005. The academic literature consistently characterizes this as a commercial decision rather than failure of efficacy or safety, with researchers noting at the time that 'intranasally and orally active GH secretagogues are useful clinical tools: so why are they not on the market?' (Laron, 2003, Journal of Endocrinology and Investigation). No further development has been registered by any company.
Hexarelin acts through two distinct receptor pathways, a duality that defines its unique pharmacological profile among GH secretagogues.
GHS-R1a pathway (shared with other GHRPs): Hexarelin binds the growth hormone secretagogue receptor type 1a in pituitary somatotrophs and hypothalamic neurons with high affinity, comparable to ghrelin. This binding activates phospholipase C and IP3-mediated calcium signaling, directly stimulating GH secretion from somatotrophs. At the hypothalamic level, hexarelin stimulates GHRH release and inhibits somatostatin tone, amplifying the pituitary GH pulse. The GH response to hexarelin is dose-dependent up to 2 mcg/kg IV, exceeds maximal GHRH, and synergizes with exogenous GHRH to produce markedly larger combined responses. The GHS-R1a pathway requires intact GHRH signaling: in patients with homozygous GHRH receptor mutations (dwarfs of Sindh), hexarelin produces no GH response despite normal ACTH and prolactin responses, confirming that GH secretion requires functional GHRH infrastructure.
CD36 pathway (hexarelin-specific cardiac mechanism): CD36 is a multifunctional scavenger receptor expressed in cardiomyocytes and cardiac microvascular endothelial cells. Hexarelin binds CD36 with high affinity; ghrelin does not displace radiolabeled hexarelin from cardiac CD36 binding sites, confirming pharmacological distinctness. CD36 binding activates downstream signaling including PI3K/Akt and MAPK/ERK pathways in cardiomyocytes, mediating anti-apoptotic, anti-fibrotic, and anti-inflammatory effects. This CD36-mediated cardioprotection occurs independently of GH secretion: it is preserved in GH-deficient, hypophysectomized, and GH-replaced rats, and the human acute cardiac studies show no correlation between GH peak and LVEF improvement.
The tachyphylaxis mechanism: Repeated stimulation of GHS-R1a leads to receptor downregulation and/or desensitization. Studies by Arvat, Ghigo, and colleagues documented progressive attenuation of peak GH responses beginning within 1 to 2 weeks of daily hexarelin administration, reaching 50 to 75% attenuation over weeks to months. This effect is partially reversible with washout periods. Whether CD36-mediated cardiac effects undergo comparable desensitization has not been systematically studied in humans.
Cortisol and prolactin elevation: Like GHRP-2 and hexarelin (compared in the Arvat 1997 study), hexarelin stimulates ACTH/cortisol release to a degree comparable to hCRH, and prolactin to a lesser extent. This non-selectivity distinguishes hexarelin from ipamorelin, which produces minimal cortisol and prolactin elevation, and is relevant for users seeking GH secretion without HPA axis activation.
Bisi et al. (1999) in 7 healthy volunteers: IV hexarelin administration increased LVEF from 64.0 plus or minus 1.5% to 70.7 plus or minus 3.0% (p less than 0.03). The effect appeared at 15 minutes, peaked at 30 minutes, and lasted up to 60 minutes. Mean blood pressure and heart rate were unchanged. Crucially, IV rhGH at a dose producing equivalent GH elevation produced no cardiac effect. This established that hexarelin's acute inotropic effect is GH-independent and intrinsic to the peptide.
Broglio et al. (2002) in 24 coronary artery disease patients during bypass surgery: hexarelin produced a prompt (within 10 minutes) increase in LVEF, cardiac index, and cardiac output (all p less than 0.001) lasting up to 90 minutes. Wedge pressure decreased (p less than 0.01). No change in systemic vascular resistance. Heart rate unchanged. Neither GHRH nor rhGH produced any hemodynamic effect. The GH response to hexarelin was far lower than rhGH despite superior cardiac effect, confirming GH-independence. The intraoperative setting provided arterial catheterization-level hemodynamic monitoring, the most rigorous measurement in any hexarelin cardiac study.
Imazio et al. (2002) in 13 patients with severe cardiomyopathy (LVEF 16 to 23%): hexarelin significantly increased LVEF in both dilated and ischemic cardiomyopathy patients. No correlation was found between peak GH elevation and LVEF improvement, again confirming GH-independence. The magnitude of LVEF improvement in these severely compromised patients is clinically noteworthy.
These three human cardiac studies form the most compelling human dataset in the hexarelin evidence base. The GH-independence is the scientifically important finding: hexarelin improves cardiac function through a distinct receptor mechanism (CD36) that other GH secretagogues and GH itself do not activate.
Three human cardiac studies using objective hemodynamic monitoring (radionuclide angiography and transoesophageal echocardiography) consistently show acute LVEF improvement following single IV hexarelin doses. The GH-independence is rigorously confirmed by both rhGH comparator arms (no effect) and the absence of GH/LVEF correlation. The studies are small (n=7 to 24) and use acute dosing -- chronic cardiovascular benefit has not been demonstrated in humans, only in animal models. Phase 2 development for CHF was discontinued before these questions could be answered in larger trials.
Repeated daily administration of hexarelin produces progressive desensitization of the GH response -- a 50 to 75% decrease in peak GH levels within weeks to months of continuous use. This is the most pronounced tachyphylaxis of any traditional GHRP. The mechanism involves GHS-R1a downregulation and/or desensitization from repeated stimulation. The tachyphylaxis is partially reversible: washout periods of several weeks restore GH responsiveness, though the time course of recovery has not been systematically characterized.
The practical implications are significant for users pursuing GH-mediated body composition benefits. If the primary goal is sustained GH elevation to drive IGF-1 production and downstream anabolic effects, hexarelin's pronounced tachyphylaxis means that full GH-releasing efficacy is lost within weeks of daily use. Continuing daily hexarelin dosing after desensitization exposes users to ongoing cortisol and prolactin elevation without the intended GH benefit -- an unfavorable risk-benefit ratio.
Cycling protocols (8 to 16 weeks on, 4 to 6 weeks off) are the standard research community approach to managing hexarelin tachyphylaxis, but the evidence base for specific cycling durations in humans is limited. The GH response attenuation in hexarelin is more pronounced and faster than that seen with ipamorelin, which produces minimal tachyphylaxis at standard research doses. For chronic GH secretagogue therapy, ipamorelin or MK-677 are pharmacologically superior choices specifically because they do not produce this rapid desensitization.
Hexarelin tachyphylaxis is a well-documented pharmacological limitation that substantially constrains its utility as a chronic GH-promoting agent. The 50 to 75% GH response attenuation within weeks is far more pronounced than with other GHRPs in this database. Users choosing hexarelin for body composition should be aware that the GH-releasing benefit degrades rapidly without strict cycling, while other adverse effects (cortisol, prolactin elevation) persist.
Imbimbo et al. (1994) established hexarelin's dose-response pharmacology in 12 healthy volunteers. Mean peak plasma GH concentrations were 3.9 ng/mL (placebo), 26.9 ng/mL (0.5 mcg/kg), 52.3 ng/mL (1 mcg/kg), and 55.0 ng/mL (2 mcg/kg), with GH peaking at approximately 30 minutes and returning to baseline within 240 minutes with a half-life of approximately 55 minutes. GH response was dose-dependent up to 1 mcg/kg, with plateau above that dose.
Arvat et al. (1997) directly compared hexarelin to GHRP-2, GHRH, TRH, and hCRH. At 1 mcg/kg IV, hexarelin and GHRP-2 produced similar, strong GH responses that significantly exceeded maximal GHRH. At 2 mcg/kg, both hexarelin and GHRP-2 again exceeded GHRH. In elderly subjects, GH responses to both hexarelin and GHRP-2 were preserved but reduced compared to young adults. The PRL response to hexarelin was lower than TRH; the ACTH/cortisol response was similar to hCRH -- the same non-selectivity profile established for GHRP-2.
Hexarelin and GHRH synergize markedly: combined administration produces GH responses described as 'massive' in the literature, substantially larger than either alone. This synergistic mechanism operates through the dual pathway: hexarelin recruits more somatotrophs into the GH pulse (via GHS-R1a and somatostatin inhibition) while GHRH increases amplitude per somatotroph.
The GHRH receptor requirement: In patients with homozygous GHRH receptor mutations (dwarfs of Sindh), hexarelin produced no GH response (less than 1 ng/mL, 50 to 100-fold below normal), despite normal ACTH and prolactin responses. This confirms that hexarelin's GH release requires intact GHRH signaling, not merely pituitary competence -- GHRH receptor signaling is required for GHRPs to release GH.
Hexarelin is the most potent traditional GHRP for acute GH release, matching GHRP-2 and exceeding maximal GHRH. This potency is well-established in multiple human Phase 1 and Phase 2 studies. However, the superior acute potency is undermined for chronic use by the pronounced tachyphylaxis. For single-dose GH provocative testing, hexarelin has been proposed as a diagnostic tool and studied in that context.
Multiple studies by Ghigo, Aimaretti, Arvat, and colleagues established hexarelin as a candidate GH provocative test for GH deficiency diagnosis in adults. The test at 0.25 to 2.0 mcg/kg IV produces reliable, reproducible GH responses in GH-sufficient individuals and significantly blunted responses in GH-deficient patients. The hexarelin plus GHRH combination test showed diagnostic sensitivity comparable to the insulin tolerance test (the reference standard) with fewer safety concerns than the hypoglycemia required by the ITT.
The cardiac findings in GH-deficient patients are pharmacologically important. Bisi et al. (1999) found that hexarelin's acute LVEF improvement in GH-deficient patients (n=7) was comparable to that in healthy volunteers, despite the GH-deficient patients having lower baseline GH. This finding, combined with the normal subject data showing no cardiac effect from rhGH at equivalent GH concentrations, confirms the cardiac mechanism is not mediated through GH at all -- it is direct CD36-mediated cardiomyocyte signaling.
The GH deficiency diagnostic work is methodologically solid and established hexarelin as a useful research tool for GH provocative testing. The diagnostic application never reached regulatory approval. The GH-deficient cardiac data is pharmacologically valuable as a confirmation of CD36-mediated mechanism. The clinical relevance of the diagnostic application is superseded by approved alternatives (GHRH plus arginine test).
Hexarelin reached Phase 2 clinical trials for two indications: GH deficiency and congestive heart failure. Both programs were discontinued in approximately 2005 by Mediolanum Farmaceutici, the developing company. The academic literature consistently describes this as a commercial or strategic decision rather than a safety failure or negative efficacy finding. The cardiovascular Phase 2 program had the most promising rationale given the acute human cardiac data.
The Laron 2003 commentary directly articulated the research community's frustration: GH secretagogues with demonstrated human utility -- hexarelin being the primary example for both GH-releasing and cardiac applications -- were not being brought to market despite Phase 2 data supporting continued development. This gap between clinical evidence and commercial development reflects the pharmaceutical industry dynamics of the early 2000s, when GH secretagogue development was commercially competitive and hexarelin's patent position may have been less favorable than other compounds.
The consequence for patients and practitioners is that hexarelin's genuine pharmacological advantages -- its unique dual mechanism, its demonstrated human cardiac effects, its oral and intranasal bioavailability -- remain in the research domain without the quality assurance, dosing standardization, and long-term safety data that regulatory review would have required.
The Phase 2 discontinuation represents a genuine loss for clinical development -- a compound with distinctive human cardiac data that was commercially abandoned rather than taken through Phase 3. This does not mean hexarelin is approved or that its efficacy in chronic settings is established. What it means is that the clinical questions -- particularly for cardiac indications -- were never definitively answered in adequately powered trials. The research community's frustration with this outcome is documented and justified.
Most potent GHRP. Shorter cycles (4-6 weeks) recommended due to receptor desensitization.
Hexarelin has weight-based IV dosing data (0.5 to 2.0 mcg/kg) from Phase 1 and Phase 2 human studies, but community use has shifted to flat subcutaneous dosing (100 to 300 mcg). The Phase 1 maximal effective dose was 1 to 2 mcg/kg IV; for a 80 kg person this equates to 80 to 160 mcg, aligning with the lower end of the community dosing range. Cycling is essential: without washout periods, the GH response deteriorates 50 to 75% within weeks, making continued hexarelin use increasingly inefficient for GH-related goals while cortisol and prolactin elevations persist. Hexarelin is explicitly named on the WADA Prohibited List S2.2 as examorelin; any use constitutes a doping violation for tested athletes. The CD36 cardiac mechanism is an ongoing research interest but no chronic cardiac protocol for human use has been validated -- the acute cardiac benefits in human studies required IV administration in hospital settings, not subcutaneous self-administration.
Within the GH secretagogue class in this database: ipamorelin (profile #7) is more GH-selective (minimal cortisol, prolactin, appetite stimulation) and produces minimal tachyphylaxis, making it the preferred choice for chronic GH secretagogue therapy. GHRP-2 (profile #53) has comparable GH-releasing potency to hexarelin with similar cortisol non-selectivity and the same Arvat 1997 head-to-head data, but lacks hexarelin's CD36-mediated cardiac mechanism. MK-677 (profile #27) is oral, produces minimal tachyphylaxis, and has the most extensive long-term human data of any GH secretagogue. Sermorelin (profile #18) and CJC-1295 (profile #8) act via the GHRH receptor rather than GHS-R1a, producing GHRH-pathway synergy with hexarelin rather than competition. For pure cardiac benefit, the hexarelin CD36 mechanism has no equivalent in the database; the closest comparison would be ghrelin (not yet profiled), which shares GHS-R1a but not CD36 cardiac selectivity.
Hexarelin's safety profile across published human studies is generally favorable, though the clinical dataset is limited to small Phase 1 and Phase 2 studies.
Acute adverse effects in controlled studies: The most commonly reported acute effects are facial flushing, transient drowsiness, and increased appetite -- all pharmacologically predictable GHS-R1a-mediated effects. Cortisol and prolactin elevation are documented, comparable to hCRH magnitude for the cortisol response (Arvat et al., 1997). No serious adverse events attributable to hexarelin were reported in any of the published human studies.
Cardiovascular effects in patients: In the Broglio 2002 intraoperative study (n=24, coronary artery disease patients), hexarelin produced the desired acute cardiac improvement without adverse hemodynamic consequences. Mean arterial pressure increased modestly; heart rate was unchanged; no arrhythmias, hypotension, or coronary events were reported. In the Imazio 2002 study (n=13, severe cardiomyopathy, LVEF 16 to 23%), the acute IV dose was well-tolerated despite the severely compromised cardiac function.
Tachyphylaxis as a practical safety concern: The pronounced GH response attenuation with chronic use is not a classical toxicity but is a significant pharmacological limitation. If users continue dosing without cycling, they are exposing themselves to all the adverse effects of hexarelin (cortisol elevation, prolactin elevation, appetite stimulation, injection site effects) while progressively losing the GH-releasing benefit. This creates an unfavorable risk-benefit evolution over time without cycling.
Uncharacterized long-term safety: No long-term controlled safety study has been conducted in humans. The Phase 2 development discontinuation in 2005 means the long-term safety dataset that would have accompanied NDA/MAA filing was never generated. Theoretical concerns from chronic GH elevation (common to all GH secretagogues) include insulin resistance, fluid retention, and concerns about proliferative effects on pre-existing neoplasia. No chronic cardiovascular safety data in humans exists beyond the short-term acute studies.
Hexarelin occupies a distinctive position in the GH secretagogue class. It is the most potent traditional GHRP for acute GH release and the only one with documented GH-independent cardiac effects in human patients, mediated through CD36 -- a receptor that ghrelin, GHRP-2, and ipamorelin do not engage with comparable affinity in cardiac tissue.
The cardiac evidence is the most important part of the hexarelin story. Three human studies using objective hemodynamic monitoring consistently show that a single IV hexarelin dose improves LVEF, cardiac output, and cardiac index in healthy volunteers, coronary artery disease patients, and severely compromised cardiomyopathy patients -- while the same doses of rhGH and GHRH produce no cardiac effect. The GH-independence is rigorously confirmed. No other peptide GH secretagogue in this database has this quality of human cardiac evidence.
The tachyphylaxis limitation is equally important to acknowledge honestly. The 50 to 75% GH response attenuation within weeks of daily use is the most pronounced of any traditional GHRP. For users seeking sustained GH elevation for body composition purposes, ipamorelin or MK-677 are pharmacologically superior choices that do not produce comparable desensitization. Hexarelin's niche for body composition purposes is primarily in cycling protocols where its high acute potency is exploited in the weeks before tachyphylaxis degrades the response.
The Phase 2 discontinuation in 2005 for commercial reasons rather than negative efficacy represents one of the more frustrating gaps in peptide clinical development. A compound with unique cardiac mechanism, demonstrated acute human cardiac benefit, and an unmet need in heart failure was commercially abandoned. The research community documented this frustration at the time. For practitioners and researchers: hexarelin's cardiac pharmacology is real and human-validated, but chronic cardiac benefit has never been demonstrated in Phase 3, and quality-controlled pharmaceutical-grade product does not exist outside a research setting.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use